FCPG: Shares could Quick-Triple by December 18th, on possible buyout

US-owned FCPG is one of only 14 drug distributors that will now dominate China's $80 billion drug market! You can score 2,800% profit if McKesson, Cardinal Health or AmerisourceBergen buys them out! Nevada-based FCPG just hit the jackpot by scoring one of just 14 licenses granted by the Chinese government to sell wholesale drugs over the Internet in China. This little US company with shares selling near $1 got its license just before the government put a moratorium on any further licensing. And they're the only US company with the Internet license! This practically guarantees a 2,800% profit on a buyout by one of the giant US drug distributors, McKesson, Cardinal Health, or AmerisourceBergen. These companies are dying to get into China, the fastest growing Pharmaceutical market in the world, but they're locked out because of the Internet license moratorium. FCPG is the #1 buyout target because it's a US company that owns a Hong Kong company that owns the Chinese drug distributor with the Internet license. Under this corporation structure, FCPG is NOT subject to China's laws, but only Hong Kong's far more business-friendly laws. This is a huge advantage because... China is right now consolidating its massive and severely antiquated drug distribution industry, which is a key part of an $850 billion gov't commitment to improve healthcare all across China by 2013. Very quickly now, the current 6,000 drug distributors (mostly unnecessary middlemen) will be slashed to just 30 or 40 modern companies, which will dominate the new $80 billion drug market! But most important, just 14 firms will be the biggest winners under consolidation because only 14 will have the Internet licenses (no business using an outmoded system will be able to compete on price, speed of delivery, or customer service). Thousands of middlemen will be eliminated and FCPG could quickly grow 28-fold! To ensure rapid growth under gov't ordained consolidation, FCPG will give a free PC to each customer that includes a direct link to the company's website, offering 30,000 Western and Chinese prescription drugs, plus thousands of over-the-counter remedies. The result will be that... Hospitals, health clinics, and drug stores will buy drugs directly from FCPG at 15% lower prices!   Profit margins for FCPG could jump by 100%! FCPG can quickly grow from $21 million to $300 million, and with double the profits, the stage could be set for a $600 million buyout by McKesson, Cardinal Health, AmerisourceBergen or Owens-Minor at $28! This is a slam dunk for investors who ACT NOW! Read the enclosed full story and score 2,800% profit on FCPG! Eric Dickson, Editor, Breakaway Stocks IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Breakaway Stocks does not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Breakaway Stocks or an offer or solicitation to buy or sell any security. First China Pharmaceutical Group, (FCPG), the company featured in this issue, appears as paid advertising, paid by Mediacom Strategies Inc. to provide public awareness for FCPG. Mediacom Strategies Inc. has approved and signed off as "approved for public dissemination" all statements made herein regarding First China Pharmaceutical Group's history, assets, technologies, current as well as prospective business operations and industry information. Breakaway Stocks and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Breakaway Stocks about FCPG. Although the information contained in this advertisement is believed to be reliable, Breakaway Stocks and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due dili- gence on this or any other advertised company. Breakaway Stocks is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $600,000 for this advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Breakaway Stocks is paid $3,000 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from First China Pharmaceutical Group's investor relations firm, or at First China Pharmaceutical Group's website www.firstchinapharma.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like First China Pharmaceutical Group, advice to investors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor pro- visions of the Private Securities Litigation Reform Act, First China Pharmaceutical Group notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.